000241156 001__ 241156
000241156 005__ 20240229154916.0
000241156 0247_ $$2doi$$a10.1002/ijc.34457
000241156 0247_ $$2pmid$$apmid:36733230
000241156 0247_ $$2ISSN$$a0020-7136
000241156 0247_ $$2ISSN$$a1097-0215
000241156 0247_ $$2altmetric$$aaltmetric:142154513
000241156 037__ $$aDKFZ-2023-00264
000241156 041__ $$aEnglish
000241156 082__ $$a610
000241156 1001_ $$aKlusa, Daria$$b0
000241156 245__ $$aDynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
000241156 260__ $$aBognor Regis$$bWiley-Liss$$c2023
000241156 3367_ $$2DRIVER$$aarticle
000241156 3367_ $$2DataCite$$aOutput Types/Journal article
000241156 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681737904_12697
000241156 3367_ $$2BibTeX$$aARTICLE
000241156 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000241156 3367_ $$00$$2EndNote$$aJournal Article
000241156 500__ $$a2023 Jun 15;152(12):2639-2654
000241156 520__ $$aAblative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness, and/or bone tropism may have a prognostic potential to identify patients profiting from the metastases-directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n=24) during radiotherapy with CellSearch, multi-color flow cytometry and imaging cytometry. Analysis of copy-number alteration indicate a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3 %) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4-expressing subpopulation representing 28.6 % of the total CTC population remained stable up to three months. At once, we observed higher chemokine CCL2 plasma concentrations and pro-inflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem-like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+ CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis-directed radiotherapy. This article is protected by copyright. All rights reserved.
000241156 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000241156 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000241156 650_7 $$2Other$$aCXCR4
000241156 650_7 $$2Other$$abone metastasis
000241156 650_7 $$2Other$$acirculating tumor cells
000241156 650_7 $$2Other$$aprostate cancer
000241156 650_7 $$2Other$$aradiotherapy
000241156 7001_ $$0P:(DE-HGF)0$$aLohaus, Fabian$$b1
000241156 7001_ $$aFranken, Andre$$b2
000241156 7001_ $$aBaumbach, Marian$$b3
000241156 7001_ $$aCojoc, Monica$$b4
000241156 7001_ $$aDowling, Paul$$b5
000241156 7001_ $$0P:(DE-He78)81b719227985a27b1b77ed6766094319$$aLinge, Annett$$b6$$udkfz
000241156 7001_ $$00000-0002-0449-8462$$aOffermann, Anne$$b7
000241156 7001_ $$aLöck, Steffen$$b8
000241156 7001_ $$aHušman, Dejan$$b9
000241156 7001_ $$aRivandi, Mahdi$$b10
000241156 7001_ $$00000-0002-3797-9975$$aPolzer, Bernhard$$b11
000241156 7001_ $$aFreytag, Vera$$b12
000241156 7001_ $$aLange, Tobias$$b13
000241156 7001_ $$aNeubauer, Hans$$b14
000241156 7001_ $$aKücken, Michael$$b15
000241156 7001_ $$aPerner, Sven$$b16
000241156 7001_ $$0P:(DE-HGF)0$$aHölscher, Tobias$$b17
000241156 7001_ $$00000-0002-3375-1500$$aDubrovska, Anna$$b18
000241156 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, Mechthild$$b19$$udkfz
000241156 7001_ $$0P:(DE-He78)f3723bca6eb95009d4c95a7590617b68$$aKurth, Ina$$b20$$udkfz
000241156 7001_ $$0P:(DE-He78)933f7d725ac87378f459623783585a1f$$aBaumann, Michael$$b21$$udkfz
000241156 7001_ $$aPeitzsch, Claudia$$b22
000241156 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34457$$gp. ijc.34457$$n12$$p2639-2654$$tInternational journal of cancer$$v152$$x0020-7136$$y2023
000241156 909CO $$ooai:inrepo02.dkfz.de:241156$$pVDB
000241156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000241156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81b719227985a27b1b77ed6766094319$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000241156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000241156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000241156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f3723bca6eb95009d4c95a7590617b68$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000241156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)933f7d725ac87378f459623783585a1f$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000241156 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000241156 9141_ $$y2023
000241156 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-25$$wger
000241156 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000241156 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000241156 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000241156 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000241156 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000241156 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000241156 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK DD zentral$$x0
000241156 9201_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x1
000241156 980__ $$ajournal
000241156 980__ $$aVDB
000241156 980__ $$aI:(DE-He78)DD01-20160331
000241156 980__ $$aI:(DE-He78)E220-20160331
000241156 980__ $$aUNRESTRICTED